The European Medicines Agency has given a positive opinion to a new fertility treatment developed by NV Organon of the Netherlands, now part of Merck & Co, that can be used as part of an assisted reproductive technology programme. ---Subscribe to MedNous to access this article--- Regulation & Policy
